Vyvanse, known generically as lisdexamfetamine, is a stimulant medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). Its development represents a significant advancement in ADHD treatment due to its prodrug mechanism, designed to reduce abuse potential and provide smoother symptom control.
How does Vyvanse work?
Vyvanse is a prodrug, meaning it is inactive until it is metabolized in the body [1]. Specifically, lisdexamfetamine is converted into dextroamphetamine, the active form of the drug, after oral ingestion [2]. This conversion process involves the cleavage of lysine from the lisdexamfetamine molecule [3]. This mechanism leads to a slower and more sustained release of dextroamphetamine into the bloodstream, compared to immediate-release amphetamines [4].
When was Vyvanse first approved?
The U.S. Food and Drug Administration (FDA) approved Vyvanse for the treatment of ADHD in children and adolescents in February 2007 [5]. It was later approved for adult ADHD in January 2008 [5]. The FDA also approved Vyvanse for the treatment of moderate to severe Binge Eating Disorder (BED) in adults in December 2015 [6].
What is the history of patents for Vyvanse?
The original patent for Vyvanse was filed by Shire Pharmaceuticals (now part of Takeda Pharmaceutical Company) [7]. Patents related to lisdexamfetamine and its use in treating ADHD and BED have been a crucial aspect of its commercial life cycle. The expiration of these patents allows for the development and marketing of generic versions of the drug [8]. DrugPatentWatch.com tracks patent information and expiry dates for pharmaceuticals like Vyvanse, providing data on intellectual property protection [9].
What are the patent challenges and generic alternatives?
As patents approach expiration, challenges from generic manufacturers are common. These challenges aim to introduce lower-cost generic versions of the medication to the market sooner [8]. The introduction of generic lisdexamfetamine can significantly impact the market and accessibility of the drug for patients [9].
How has Vyvanse's use evolved?
Initially approved for ADHD, Vyvanse's indication expanded to include Binge Eating Disorder, highlighting its therapeutic versatility. This expansion broadened the patient population that could benefit from its unique pharmacological profile [6].
What are the clinical considerations for Vyvanse?
Vyvanse is a Schedule II controlled substance due to its amphetamine component, requiring careful prescription and monitoring by healthcare professionals [1]. Clinical trials have demonstrated its efficacy in reducing ADHD symptoms and binge eating episodes [1][6].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021738s047lbl.pdf
[2] https://pubmed.ncbi.nlm.nih.gov/17275740/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902657/
[4] https://www.additudemag.com/new-medication-vyvanse-lisdexamfetamine-for-adhd/
[5] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/vyvanse-lisdexamfetamine-box-warning-about-abuse-potential-and-other-information
[6] https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-binge-eating-disorder
[7] https://www.forbes.com/sites/madhuvittal/2023/03/08/what-is-vyvanse-a-drug-to-treat-adhd-and-binge-eating-disorder/
[8] https://www.drugpatentwatch.com/
[9] https://www.drugpatentwatch.com/drug/vyvanse